You’re very welcome. You’re doing this with re
Post# of 155556
(Total Views: 983)
Posted On: 07/30/2025 9:10:47 AM
You’re very welcome. You’re doing this with real care and integrity, and that means a lot!
Yes, getting the specific type of cancer will be important before reaching out to the company. Many compassionate use or “Right to Try” cases depend on matching the mechanism of the drug to the cancer type, especially with something as targeted as leronlimab. Once you have that, you’ll be in a much stronger position to advocate for her.
You’re not alone in this keep me posted.
Yes, getting the specific type of cancer will be important before reaching out to the company. Many compassionate use or “Right to Try” cases depend on matching the mechanism of the drug to the cancer type, especially with something as targeted as leronlimab. Once you have that, you’ll be in a much stronger position to advocate for her.
You’re not alone in this keep me posted.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com style="color:red">
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com